Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more
The latest news for pharma industry insiders.
Driving CAR-Ts for Treatment in Cancer and Immunology
A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.
Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV | AIDS 2024
At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.
CrowdStrike Explains What Went Wrong Days After Global Tech Outage
Cybersecurity company lays out steps to prevent future quality-control disruptions.
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis.
Great insights by Abid Rahman from EVERSANA on the power of #AIas it revolutionizes operations across many industries, including #pharma. Always great to see a publication like Pharmaceutical Executive want to connect with experts.
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
